イタリアでのCAR-T細胞療法に最適なクリニックと費用をご発見ください2026

CAR T-cell therapy is available in Italy as a standard treatment for relapsed or refractory hematological malignancies like lymphoma and leukemia. The Italian Medicines Agency (AIFA) regulates these therapies, which are primarily delivered through specialized IRCCS-accredited research hospitals and university clinics.

• Approved treatments: Facilities offer advanced CAR T products including Kymriah (tisagenlecleucel) and Carvykti.
• Leading centers: Major hubs include San Raffaele in Milan and Bambino Gesù in Rome.
• Eligibility criteria: AIFA recently raised the age limit to 75 years for certain indications.
• Cost range: Full clinical pathways for international patients range from $350,000 to $500,000.

Bookimed Expert Insight: While northern Italy clinics like San Raffaele handle the highest patient volumes, data shows a trend where centers in southern Italy, such as Cardarelli Hospital in Naples, may offer faster navigation through administrative bureaucracy. Patients should compare wait times across regions, as northern hubs often face higher demand despite having more facilities.

Patient Consensus: Seeking treatment early is vital as intensive prior chemotherapy can impact eligibility. Patients frequently note that the pre-approval process is rigorous and may require several months of waiting.

Eligibility for CAR T-cell therapy in Italy requires patients to have relapsed or refractory hematological cancers. Candidates must fail at least two prior lines of systemic therapy. The Italian Medicines Agency governs access through specialized hub centers like San Raffaele in Milan.

• Disease status: Limited to refractory lymphoma, leukemia, or myeloma after standard treatments fail.
• Age requirements: Patients up to 75 years for lymphoma and 25 for leukemia.
• Physical fitness: Requires ECOG status 0–1 and adequate heart, kidney, and lung function.
• Life expectancy: Candidates must have a projected life expectancy of at least 12 weeks.

Bookimed Expert Insight: While Italy follows European Medicines Agency standards, the Italian Medicines Agency often sets stricter age caps. Professor Fabio Ciceri at San Raffaele leads critical cell therapy trials that may offer earlier access. Patients often wait 3–6 months for manufacturing, so early referral to a hub is vital.

Patient Consensus: Many find the approval process rigorous and sometimes describe it as a lottery. Moving quickly between treatment lines is essential to remain healthy enough for the manufacturing period.

Italy's national healthcare system (Servizio Sanitario Nazionale) fully covers CAR T-cell therapy for eligible patients. The Italian Medicines Agency (AIFA) grants these treatments innovation status, meaning public funding applies at authorized hematology centers for specific relapsed or refractory B-cell malignancies and multiple myeloma.

• Approved indications: Covers B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
• Clinical criteria: Patients must have failed at least two lines of prior systemic therapy.
• Authorized centers: Treatment occurs at specialized IRCCS-accredited facilities like Ospedale San Raffaele in Milan.
• Age limits: Coverage extends to patients up to 75 years for specific approved therapies.

Bookimed Expert Insight: While Italy offers full public coverage, the concentration of authorized centers in Lombardy and Lazio creates significant geographic disparities. Patients often choose San Raffaele because it combines IRCCS research accreditation with massive clinical volume, serving 300,000 patients annually. This helps navigate the complex AIFA drug registry requirements faster than smaller regional hospitals.

Patient Consensus: Patients emphasize that while treatment is free for citizens, the approval process can take 6 months. Many suggest starting the eligibility verification early at AIFA-approved centers to manage the 3-to-12 month waiting periods effectively.

Italy is a global leader in CAR T-cell therapy, with San Raffaele in Milan and Bambino Gesù Children Hospital in Rome serving as primary hubs. These AIFA-authorized centers specialize in cell and gene therapy clinical trials for adult hematology and pediatric neuroblastoma.

• San Raffaele Milan: Primary adult hub led by Professor Fabio Ciceri for complex hematological cancers.
• Bambino Gesù Rome: Global leader in pediatric immunotherapy and neuroblastoma CAR-T treatment development.
• Careggi University Hospital: Authorized academic center providing licensed therapies like Yescarta and Kymriah.
• Humanitas Research Hospital: Specialized oncology institute focusing on advanced immunotherapy protocols for lymphoma.

Bookimed Expert Insight: Data shows San Raffaele maintains a unique position by integrating world-first stem cell breakthroughs with CAR-T delivery. While many centers offer standard protocols, Milan's IRCCS-accredited facilities manage significantly higher patient volumes. This concentrated experience often leads to more robust multidisciplinary follow-up for complex immune responses.

Accessing CAR T-cell therapy in Italy is hindered by uneven geographic distribution of centers, complex regional reimbursement processes, and strict eligibility criteria. While AIFA-approved, 70% of qualified clinics are concentrated in four northern and central regions, leaving five southern regions without local access.

• Geographic disparities: Treatment hubs are limited to cities like Milan and Rome, requiring patient relocation.
• Reimbursement delays: Transitioning from national to regional funding creates administrative bottlenecks and lengthy local appeals.
• Regulatory bottlenecks: AIFA often maintains stricter age and fitness limits than standard EMA guidelines.
• Referral fragmentation: Lack of a national referral system causes delays in identifying eligible patients.

Bookimed Expert Insight: While standard CAR T pathways involve long waits, Milan remains the strategic choice for international and local patients. Clinics like San Raffaele combine massive clinical research with high-volume hematology departments. Their role in gene therapy trials often provides earlier access to technology than smaller regional centers.

Patient Consensus: Patients report that while public coverage exists, the 6 to 12-month wait times often necessitate early involvement of advocacy groups. Most recommend securing complete treatment documentation immediately to expedite the complex reimbursement appeals process.